New Jersey Pharmaceutical Company Settles Medicaid Fraud Allegations for $2M
Dey is a pharmaceutical company that specializes in developing and manufacturing prescription drug products, such as EpiPen, EMSAM and Perforomist, for the treatment of respiratory disease, severe allergic reactions and psychiatric disorders.
Federal regulations place limits on the amount Wisconsin Medicaid can pay for reimbursement of prescription drugs. In order comply with those limits, Wisconsin estimates the acquisition cost providers pay to obtain prescription drugs that are later prescribed to Medicaid recipients. The state relies on average wholesale prices published by a pricing compendium, First DataBank. Wisconsin alleged Dey manufacturers reported inflated average wholesale prices to First DataBank in order to deceive the Medicaid pharmaceutical reimbursement program for increased sales and market share.
Read the AG's news release about Dey's settlement.
Read other coverage about pharmaceutical company settlements:
- Forest Pharmaceutical to Pay $313M to Settle Criminal and Civil Charges, Including Paying Kickbacks to Physicians
- Pharmaceutical Company to Pay $27M for Medicaid Fraud
- Pharmaceutical Company Teva Settles Drug-Pricing Lawsuits
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- The Future of ACOs for Anesthesiologists
- Healthcare Exchange Traded Funds See Biggest Boom in Years
- FDA Issues Draft Guidance on Off-Label Use Information Dissemination
- Surgical Care Affiliates President & CEO Andrew Hayek Among 2014 Aspen Institute Henry Crown Fellows
- A Look at ASC Valuation Through the Eyes of M&D Companies